New hope for Tough-to-Treat lymphoma: experimental pill shows promise
NCT ID NCT07545603
First seen Apr 23, 2026 · Last updated May 14, 2026 · Updated 1 time
Summary
This study tests an experimental drug called XNW5004 in 65 adults with follicular lymphoma (a slow-growing blood cancer) that has returned or stopped responding after at least three prior treatments. Participants take the drug twice daily for 28-day cycles. Researchers will measure how many patients' tumors shrink or disappear, and track side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA, GRADE 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospitial
RECRUITINGBeijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.